NantKwest (NASDAQ:NK) Rating Reiterated

NASDAQ:NK is currently trading 4.15% higher at $3.63 as of 6:01 AM New York time. NantKwest’s stock is 0% in the past 200 days. It has underperformed the S&P500, which has gained 13.56% in the same time.

Out of 6 analysts covering NantKwest, 0 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $38 and the lowest is $10 according to Thomson/First Call. The 12-month mean target is $26.17, which means upside potential of 620.94% over the current price.

NantKwest (NASDAQ:NK) Profile

NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs).

NantKwest (NASDAQ:NK) traded up 4.15% on 17 March, hitting $3.63. A total of 577,754 shares of the company’s stock traded hands. This is up from average of 271,890 shares. NantKwest has a 52 week low of $3.44 and a 52 week high of $10.26. The company has a market cap of $299.43M and a P/E ratio of 0.

Get the latest NantKwest (NASDAQ:NK) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post FBR & Co. Reconfirms a Outperform Rating on NantKwest (NASDAQ:NK) and $9.0 Target appeared first on Octafinance.